These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37754568)

  • 1. Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients.
    Midaglia L; Rovira A; Miró B; Río J; Fissolo N; Castilló J; Sánchez A; Montalban X; Comabella M
    Eur J Neurol; 2024 Jan; 31(1):e16077. PubMed ID: 37754568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
    J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
    Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32817406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up.
    Ayrignac X; Aouinti S; Vincent T; Carra-Dallière C; Charif M; Duflos C; Hirtz C; Dos Santos A; Menjot de Champfleur N; Labauge P; Lehmann S
    Mult Scler Relat Disord; 2024 Sep; 89():105747. PubMed ID: 39053395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
    Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study.
    Kızılay T; Akbayir E; Erol R; Demir AS; Özkan Yaşargün D; Yilmaz V; Tuzun E; Turkoglu R
    Eur Neurol; 2024; 87(4):203-210. PubMed ID: 38754397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
    Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
    Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
    Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
    Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
    J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
    Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
    Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
    Kuhle J; Plavina T; Barro C; Disanto G; Sangurdekar D; Singh CM; de Moor C; Engle B; Kieseier BC; Fisher E; Kappos L; Rudick RA; Goyal J
    Mult Scler; 2020 Nov; 26(13):1691-1699. PubMed ID: 31680621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode.
    Plavina T; Singh CM; Sangurdekar D; de Moor C; Engle B; Gafson A; Goyal J; Fisher E; Szak S; Kinkel RP; Sandrock AW; Su R; Kieseier BC; Rudick RA
    JAMA Netw Open; 2020 Nov; 3(11):e2016278. PubMed ID: 33151313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.
    Niiranen M; Kontkanen A; Jääskeläinen O; Tertsunen HM; Selander T; Hartikainen P; Huber N; Solje E; Haapasalo A; Kokkola T; Lohioja T; Herukka SK; Simula S; Remes AM
    Mult Scler Relat Disord; 2021 Nov; 56():103280. PubMed ID: 34627002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosis.
    Wenger KJ; Hoelter MC; Yalachkov Y; Hendrik Schäfer J; Özkan D; Steffen F; Bittner S; Hattingen E; Foerch C; Schaller-Paule MA
    Eur J Radiol; 2023 Sep; 166():111019. PubMed ID: 37549559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
    Kuhle J; Kropshofer H; Haering DA; Kundu U; Meinert R; Barro C; Dahlke F; Tomic D; Leppert D; Kappos L
    Neurology; 2019 Mar; 92(10):e1007-e1015. PubMed ID: 30737333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
    Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
    Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.